Waratah Capital Advisors’s Pfizer PFE Stock Holding History

Waratah Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-24,093	Closed	-$669K	–	170
2024 Q1	$669K	Buy	24,093 +15,121	+169%	+$420K	0.02%	125
2023 Q4	$258K	Buy	+8,972	New	+$271K	0.01%	149
2014 Q3	–	Sell	-45,954	Closed	-$1.29M	–	58
2014 Q2	$1.29M	Sell	45,954 -22,345	-33%	-$637K	0.63%	35
2014 Q1	$2.08M	Buy	68,299 +28,142	+70%	+$839K	1.15%	22
2013 Q4	$1.17M	Buy	+40,157	New	+$1.17M	0.45%	53

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Waratah Capital Advisors's PFE Position: Q2 2024 in Review

Waratah Capital Advisors sold out of Pfizer (PFE) in Q2 2024, closing a stake of 24,093 shares — an estimated $669K sold.

Waratah Capital Advisors first reported a position in PFE in Q4 2013 and held it in 5 quarters. The position peaked at $2.08M in Q1 2014. 2,873 funds tracked by Wall St. Rank hold PFE as of Q2 2024.

Waratah Capital Advisors reported no remaining Pfizer position as of Q2 2024 after selling out during the quarter.
Waratah Capital Advisors sold 24,093 Pfizer shares in Q2 2024, an estimated $669K.
Waratah Capital Advisors first reported a position in Pfizer in Q4 2013 and held it in 5 quarters.
Waratah Capital Advisors's Pfizer position peaked at $2.08M in Q1 2014.
2,873 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.

Based on Waratah Capital Advisors's 13F filing for Q2 2024, filed 12 Aug 2024.